par Brandao, Marianna;Pondé, Noam;Piccart-Gebhart, Martine 
Référence Future oncology, 15, 2, page (207-224)
Publication Publié, 2019-01
Référence Future oncology, 15, 2, page (207-224)
Publication Publié, 2019-01
Article révisé par les pairs
| Résumé : | The number of breast cancer (BC) cases is growing worldwide, being most frequently diagnosed in the early-setting. Mammaprint™ is a 70-gene-expression signature, originally designed for selecting early BC patients with low risk of developing metastasis, so that they could be spared adjuvant chemotherapy. Its use as a prognostic biomarker has been extensively validated, both retrospectively and prospectively. However, its value as a predictive tool and as a clinically useful tool remains controversial. This review will describe how the test works, its application in the clinic and its limitations. Cost-effectiveness studies will be summarized. Finally, we will provide a perspective on the use of Mammaprint in the near future, as a valuable tool for personalizing the treatment of early BC patients. |
